Xenoport: Investor Presentation (Xenoport) - Oct 17, 2014 - "XP21279 Phase 2 Study in Advanced Parkinson's Patients"; "Minimal Fluctuation in Levodopa Blood Levels"; "Achieved levodopa levels with XP21279/Carbidopa tablet within the target therapeutic window"
P2 data • Parkinson's Disease
|